Hi 1S1,
The analgesic market was always at the core of some of the leading directors, both at OBJ as well as at PNO.
I therefore believe that one of the earliest large partnering companies is still pursuing the naltrexone, or a similar analgesic pharmaceutical agent, patch due to the great results in this study.
The gold nanoparticle delivery testing which was performed during the same time period has led many here to assume that nanoparticle delivery might be at the forefront of OBJ testing regimes with partners, in particular for cancer treatments.
The description in the announcement today is very much fitting the patent description of PNO's recently approved patent for one of their main Tripeptofen applications.
If you compare the wording, it does sound intriguingly similar.
The timing of the patent release is very coincidential if assumed it is not related to an announcement of the sister company for developing pain patches a month later.
I therefore am of the opinion that one pharmaceutical partner is developing a prescription analgesic patch to control opioid delivery, reduce the amount of medicine necessary to be prescribed and minimize the possibility of abuse which represents a large problem with long term opioid drugs descriptions ( hence the extremely long regulatory hurdles to clear ).
On the other hand, OBJ is now pursuing as well the OTC pain patch to reduce musculoskeletal pain which is excactly what PNO specialises in.
Ann: Pain Patch Development Program , page-38
-
- There are more pages in this discussion • 7 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add WFL (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.3¢ |
Change
0.000(0.00%) |
Mkt cap ! $1.478M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
| WFL (ASX) Chart |
Day chart unavailable